Rejuvine Life Sciences

Rejuvine Life Sciences

Open  for investment

About this raise

Rejuvine Life Sciences is raising funds on Silicon Prairie Online. The company is revolutionizing the natural health sector by integrating ancient wisdom with modern science. Rejuvine Life Sciences’ flagship product, Skordo Plus, offers a herbal solution for diabetes management to control blood sugar and manage overall well-being. The company holds US and Indian patents for its anti-diabetic formulations and plans to offer additional products for women’s health and pain relief. Theenathayalan Parthasarathy founded Rejuvine Life Sciences in February 2023. The current crowdfunding campaign has a minimum target of $100,000 and a maximum target of $1.24 million. The campaign proceeds will be used for research and development, office equipment, salaries and fees, business development, events, sales and marketing, production, and office expenses.

Expand

Investment Overview

Committed this round: $4,500

Deal Terms

Total Commitments ($USD)

Platform
Silicon Prairie Online
Start Date
04/18/2024
Close Date
04/17/2025
Min. Goal
$10,000
Max Goal
$1,235,000
Min. Investment

$1,000

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$40,000,000

Company & Team

Company

Year Founded
2023
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
Low
Location
Middletown, Delaware
Business Type
Growth
Company Website
Visit Website

Team

Employees
10
Prior Founder Exits?
No
Founder Name
Pat Theenathayalan
Title
CEO
Founder Name
Sudhir Agrawal
Title
CFO

Financials

as of Fiscal Year 2023
 Revenue
$4,230
 Monthly Burn
$31,634
 Runway
0.9 months

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$4,230

$0

COGS

$5,076

$0

Tax

$17,277

$0

 

 

Net Income

$-205,500

$0

Summary Balance Sheet

FY 2023 FY 2022

Cash

$30,950

$0

Accounts Receivable

$4,000,000

$0

Total Assets

$205,052

$0

Short-Term Debt

$0

$0

Long-Term Debt

$3,910,000

$0

Total Liabilities

$3,910,000

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$0
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/17/2025 Silicon Prairie Online $40,000,000 $4,500 Equity - Common Active RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Rejuvine Life Sciences on Silicon Prairie Online 2024
Platform: Silicon Prairie Online
Security Type: Equity - Common
Valuation: $40,000,000
Price per Share: $1.00

Follow company

Follow Rejuvine Life Sciences on Silicon Prairie Online 2024

Buy Rejuvine Life Sciences's Deal Report

Rejuvine Life Sciences Deal Report

Get Kingscrowd's comprehensive report on Rejuvine Life Sciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Rejuvine Life Sciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Rejuvine Life Sciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge